Grufity logo
Grufity logo
NRBO

NRBO - NeuroBo Pharmaceuticals Inc Stock Price, Fair Value and News

$1.89 
Market Closed as of 29 Jan 2025, 04:00 pm ET

Price Targets

NRBO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRBO Price Action

NRBO RSI Chart

NRBO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NRBO Valuation

Market Cap

9.9M

Price/Earnings (Trailing)

-0.76

EV/EBITDA

0.3

Price/Free Cashflow

-0.65

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

NRBO Fundamentals

NRBO Earnings

Earnings (TTM)

-13.1M

Earnings Growth (Yr)

-4.14%

Earnings Growth (Qtr)

-98.08%

NRBO Profitability

Return on Equity

-144.66%

Return on Assets

-91.22%

Free Cashflow Yield

-153.17%

NRBO Investor Care

Shares Dilution (1Y)

453.46%

Diluted EPS (TTM)

-3.6

Revenue & Growth

How NeuroBo Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

About NeuroBo Pharmaceuticals Inc

NRBO
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEneurobopharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2

NeuroBo Pharmaceuticals Inc Frequently Asked Questions

NRBO is the stock ticker symbol of NeuroBo Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of NeuroBo Pharmaceuticals Inc is 9.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.